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Abstract
Background: Hematological abnormalities such as anemia, neutropenia, and thrombocytopenia occur in children 
infected by the human immunodeficiency virus (HIV). These abnormalities are due to myelosuppression caused by 
the HIV and contribute to the morbidity and mortality of HIV‑infected children. Malnutrition is prominent in HIV‑infected 
children due to associated conditions such as oropharyngeal candidiasis, diarrhea, and cytokine production which result 
in poor intake, nutrient loss, and increased metabolic rate, respectively.
Objectives: To determine the prevalence of hematological abnormalities (using the World Health Organization (WHO) 
case definitions) and malnutrition in HIV‑infected children receiving care at the University of Nigeria Teaching 
Hospital, Enugu.
Materials and Methods: The hematological and anthropometric indices of HIV‑infected children between 18 and 
59 months were assessed. Their hemoglobin level, neutrophil, and platelet counts were the hematological profiles 
evaluated using the WHO case definitions in HIV clinical staging. The weight‑for‑height z‑score index was used to assess 
the nutritional status of subjects using the WHO reference ranges. The t‑test, Chi‑square, and Pearson correlation 
coefficient were used for statistical analysis.
Results: There were 67 HIV positive children: 34 males and 33 females, aged 18‑59 months. The mean hematological 
levels of subjects were hemoglobin (Hb) 10.4 ± 1.2 g/dl, neutrophil count 3,031 ± 1,039 cells/mm3, platelets count 
294 ± 78 × 109/L. Two children (3.0%) had anemia (hemoglobin < 8 gm/dl) and were severely immunosuppressed, 
on highly active antiretroviral therapy treatment and had advanced HIV disease (clinical stage 3). Children who were 
malnourished were 15 (22.4%).
Conclusion: Hematological abnormalities and malnutrition occur in HIV positive children.
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Introduction
The human immunodeficiency virus (HIV) infection accounts 
for more than 36% rise in under‑five mortality in Africa.[1] 
Enugu state, had a seroprevalence rate of 5.8% as of 2008.[2]
Hematological abnormalities such as anemia, neutropenia, 
and thrombocytopenia occur in children infected by 
HIV[1,3,4] and the etiology is multifactorial.[4] HIV infection 
causes elaboration of cytokines, depressing hemopoeisis, 
and resulting in hematological abnormalities.[5] Some 
opportunistic infections such as tuberculosis[6,7] and some 
antiretroviral drugs like zidovudine, are known to cause 
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anemia due to myelosuppression.[3,5‑7] Ruhinda et al.,[8] in 
Uganda found anemia to be prevalent in 57.6% children 
aged 3 months‑18 years with HIV infection. Bachou and 
colleagues[9] documented 8.0% prevalence for severe anemia 
in children below 60 months of age. It has been noted that 
certain conditions prevalent in HIV‑infected children, such 
as micronutrient malnutrition (iron and folate deficiencies), 
determine to a large extent, the prevalence of anemia 
particularly.[1] Childhood malnutrition among HIV‑infected 
children is due to decreased food intake, increased nutrient 
loss from malabsorption, and diarrhea and also increased 
metabolic rate.[1] In the study by Bachou et al., 43.0% 
of the children below 60 months of age had edematous 
malnutrition.[9]
There is yet no available published work on hematological 
abnormalities and malnutrition in HIV positive children in 
Nigeria. This study therefore was conducted to determine 
the prevalence of hematological abnormalities and 
malnutrition in HIV positive children aged between 18 
and 59 months.
Materials and Methods
Study center and design
The study was conducted at the Pediatric Infectious Disease 
Clinic of the University of Nigeria Teaching Hospital. The 
clinic was established in 2005 to cater primarily for children 
with HIV exposure and infection. Children seen in the clinic 
are from referrals from the other clinics within and outside 
the hospital. This was a cross‑sectional descriptive study in 
which subjects were recruited and enrolled by convenient 
sampling method on having given informed written consent 
and meeting the inclusion criteria for the study. The sample 
size of 67 children was used. This was determined with the 
size formula (in a descriptive study) for a proportion for 
population size of less than 10,000.[10]
Subject selection
For a participant’s enrolment the following criteria were 
used: Age between 18 and 59 months, diagnosis of HIV 
with ELISA test and confirmation by Western blot (at 
the time of this study, our center does not carry out DNA 
polymerase chain reaction for early infant diagnosis). 
The use of antiretroviral medications, cotrimoxazole and 
presence of opportunistic infections such as pneumocystis 
jiroveci pneumonia (PCP) and tuberculosis were not 
exclusion criteria.
Methodology
On presentation to the clinic, data on gender, age, 
highly active antiretroviral therapy (HAART) use and 
duration, duration of HIV diagnosis, and CD4 cell count 
and percent were obtained. The physical examination 
findings of the subjects were also documented. The 
weight and the height of the subjects were measured 
using a combined measuring instrument Health Weighing 
Scale and Stadiometer (RTZ‑120A, HECOS, China) 
with respective sensitivities of 0.1 kg and 0.1 cm. The 
weighing scales were standardized each day of the study 
using known weights to ensure consistent and accurate 
measurements. About 3 ml of subject’s blood were collected 
in ethylenediaminetetraacetic acid (EDTA) bottles 
and analyzed for full blood count (FBC) using Sysmex 
Haematolog Analyzer, (Europe, serial number A8206). The 
blood samples were analyzed within 24 h of collection and 
were not refrigerated.
The data obtained were used to categorize the subjects. 
Advanced HIV disease was defined as WHO clinical 
stage 3 and 4, while stage 1 and 2 defined nonadvanced 
HIV disease.[1] Duration of HIV diagnosis is the time 
from diagnosis of HIV in the subject to the time of the 
study. Using the WHO stratification for age‑related CD4 
values,[1] the HIV‑positive under‑five children, were stratified 
into two different age groups; 18‑35 months (Group 1) and 
36‑59 months (Group 2). Severe immunosuppression 
was defined as CD4% of less than 25% for Group 1 
and CD4% of less than 20% for Group 2.[11] The 
anthropometric values of weight and height were used to 
classify the nutritional status of the children using the World 
Health Organization (WHO) weight‑for‑height z‑score 
charts.[12] Values from above‑1 standard deviation (SD) 
to + 1SD defined well‑nourished children while malnutrition 
was defined as the index‑1SD and below.[13] Weight‑for‑height 
z‑score less than‑1SD to‑2SD was mild malnutrition, 
below‑2SD to‑3SD was moderate malnutrition, while values 
below‑3SD was severe malnutrition.[13] Using the WHO 
case definition of hematological indices,[11] anemia was 
defined as hemoglobin concentration of less than 8 g/dl, 
neutropenia was absolute neutrophil count of less than 
1,000/mm3 and thrombocytopenia was platelet count of less 
than 50,000/mm3 (50 × 109/l).[11]
Ethical approval was obtained from Health Research 
and Ethics Committee of University of Nigeria Teaching 
Hospital (UNTH), Enugu before commencing the study. 
The subjects’ data were safely stored and the confidentiality 
of information obtained was secured.
Demographic and laboratory data were analyzed using 
the Statistical Package for Social Sciences (SPSS) 
version 15.0 for Windows® (IBM Inc, Chicago Illinois, 
USA). Continuous variables such as the age, duration of 
HAART, and hematological indices were expressed as mean 
and standard deviations, median, and range. Comparison 
of means of continuous variables was done using t‑test and 
analysis of variance (ANOVA). For categorical variables, 
Chi‑squared test (Fisher’s exact test, if indicated) was used 
for test of significance. To ascertain relationships between 
hemoglobin levels and subjects’ characteristics, Pearson 
Ezeonwu, et al.: Hematological nutritional HIV children
305Nigerian Journal of Clinical Practice • May-Jun 2014 • Vol 17 • Issue 3
correlation coefficient was used for continuous variables. 
Significant levels were set with P < 0.05.
Results
A total of 67 children were enrolled. There were 34 males, 
with a male: female ratio of 1:1. The median age of the study 
population was 48 months (range of 27‑59 months), while 
the mean duration of HIV diagnosis and HAART treatment 
were 13.9 ± 10.4 (95% CI, 11.3‑16.4, P < 0.0001) and 
10.1 ± 10.0 months (95% CI, 7.6‑12.6, P ≤ 0.0001), 
respectively. Majority (71.6%, 48/67) was on HAART, 
Table 1 and the HAART regimen included zidovudine for 
all those on HAART. All the children were on cotrimoxazole 
prophylaxis. The mean values of the hematological indices 
are shown in Table 2.
Only two subjects (all females) had anemia with equal 
occurrence in each age groups (Fisher’s exact = 0.27, 
P = 1.000), giving a prevalence of anemia in HIV 
positive children as 3.0%, (2/67). The anemic subjects 
were older (mean age = 47.0 ± 17.0 months, 95% 
CI, 105.5‑199.5) than those without anemia (mean 
age = 44.3 ± 9.5 months, 95% CI 41.9‑46.6), P = 0.697. 
The mean CD4% of anemic subjects was 11.5 ± 2.1 (95% 
CI, ‑7.2 to 30.4) compared to those without anemia 
22.3 ± 9.6 (95% CI, 19.9‑24.7), P = 0.121. The two 
subjects who had anemia were severely immunosuppressed, 
had advanced HIV disease were on HAART and 
malnourished [Table 3]. The remaining 46 children on 
HAART were not anemic. None of the subjects had 
neutropenia or thrombocytopenia. However, there was 
comparatively low neutrophil count in those on HAART 
treatment, t = 0.662, P = 0.062; Table 3. A direct 
relationship was demonstrated between CD4% and 
hemoglobin level; r = 0.40, P = 0.001 [Table 4].
Fifteen of the children (22.4%, 15/67) were malnourished, 
and there were more males than females and more of 
the older age group; χ2 = 0.796, P = 0.851; χ2 = 5.455, 
P = 0.141; respectively [Table 5]. Of this number, seven were 
on HAART (χ2 = 5.934, P = 0.015), two had advanced 
HIV disease (Fisher’s exact = 7.147, P = 0.047), two 
were anemic (Fisher’s exact = 7.147, P = 0.047), and six 
were severely immunosuppressed (χ2 = 2.578, P = 0.108). 
The malnourished children had shorter duration of HIV 
diagnosis and HAART treatment than well‑nourished 
children [Table 6]. There was a direct correlation between 
the weight‑for‑height z‑score and age of subjects, duration 
of HIV diagnosis, and duration of HAART [Table 7].
Discussion
The only hematological abnormality seen in this study was 
anemia with a prevalence rate of 3.0%. Anemia has been 
documented by several studies[1,3,4,8,9,14,15] as a common 
hematological abnormality in HIV‑infected children. 
Contrary to the low prevalence rate in this study, Adetifa 
et al.,[3] Ira[4] with their colleagues found the prevalence of 
anemia to be 77.9 and 70%, respectively. Bachou et al.,[9] 
documented 8.0% prevalence for severe anemia. This 
marked difference could be from the varied definitions 
ascribed to anemia by the different studies; whereas, the 
index study used WHO case definition for anemia as 
documented in WHO clinical staging system for HIV: 
Hb < 8 g/dl, in HIV positive children.[11] Adetifa and 
colleagues defined it as Hb < 10 g/dl,[3] while Ira and 
Bhushan used Hb < 11 g/dl.[4] These[3,4] were higher values 
Table 1: General characteristics of the study population
Parameters WHO clinical staging Total
Stage 1 Stage 2 Stage 3 Stage 4
M* F** M F M F M F
Medication
On HAART
18-35 months 4 3 1 2 0 1 0 0 48 (71.6)
36-59 months 14 13 6 3 0 1 0 0
Not on HAART
18-35 months 5 4 1 1 0 0 0 0 19 (28.4)
36-59 months 2 4 1 1 0 0 0 0
Total 49 (73.1) 16 (23.9) 2 (3.0) 0 (0) 67 (100)
Immunosuppression
Severe
CD4% <25 for 18-35 months 2 2 1 2 0 1 0 0 24 (35.8)
CD4% <20 for 36-59 months 6 5 2 2 0 1 0 0
Non severe
CD4% ≥25 for 18-35 months 7 5 1 1 0 0 0 0 43 (64.2)
CD4% ≥20 for 36-59 months 10 12 5 2 0 0 0 0
*M=Male, **F=Female, HIV=Human immunodeficiencyvirus, HAART=Highly active antiretroviral therapy
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representing moderate and mild anemia, respectively[16] and 
may have contributed to higher prevalence rates. However, 
Bachou et al., used Hb < 5 g/dl for severe anemia in 
HAART naïve children below 60 months of age.[9]
The high CD4 cell count of our subjects may have 
contributed to the low prevalence of anemia, as HIV 
positive children with high CD4 cell count are less likely to 
have anemia.[7,14] Mata‑Marín and others[17] in their study 
documented CD4 cell count below 200 cells/mm3 (severe 
immunosuppression) as the only risk factor associated 
with anemia in their subjects. In the study by Ruhinda 
et al.,[8] advanced disease, low CD4 cell count young 
age (age range of study population 3 months‑18 years) 
were risk factors associated with anemia. Interestingly, our 
subjects with anemia were all severely immunosuppressed 
and had advanced HIV disease. One of the etiologies of 
anemia in HIV infection is suppression of erythropoiesis by 
Table 2: Hematological indices of the study population
Indices Parameters
Mean±SD 95% CI
Hemoglobin g/dl 10.4±1.2 10.1-10.7
Neutrophil count in cells/mm3 3,031±1,039 2,778-3,284
Platelet count×109/l 294±78 275-313
SD=Standard deviation, CI=Confidence interval
Table 3: Subject’s characteristics and hematological 
indices









On HAART 10.2±1.2 2883.1±988.2 289.9±82.4
Not on HAART 11.1±1.2 3406.6±1095.7 303.4±68.1








t (P value) 0.056 (< 0.001) 0.546 (0.876) 0.696 (0.121)
Immunosuppression
Severe 9.9±1.4 3104.2±912.2 269.3±88.9
Nonsevere 10.7±1.0 2991.0±1111.7 307.4±69.2
t (P value) 0.204 (0.006) 0.230 (0.672) 0.245 (0.056)
Nutritional status
Well-nourished 10.5±1.1 3016.5±1008.6 294.3±71.9
Malnourished 10.3±1.6 3083.5±1173.3 291.8±100.5
t (P value) 0.066 (0.716) 0.687 (0.828) 0.148 (0.913)
HIV=Human immunodeficiency virus, HAART=Highly active antiretroviral 
therapy, SD=Standard deviation
Table 4: Correlation between haemoglobin level and age 
of subjects, duration of HIV infection, duration of HAART 




Age of subjects in months −0.068 0.583
Duration of HIV infection in months −0.083 0.506
Duration of HAART treatment in months −0.125 0.315
Weight-for-height of subjects −0.088 0.477
CD4% 0.390 0.001
HIV=Human immunodeficiency virus, HAART=Highly active antiretroviral 
therapy
Table 5: Nutritional abnormalities by age and gender






18-35 months 15 (28.8) 6 0 1 22
36-59 months 37 (71.2) 4 3 1 45




χ2 (P value) 5.455 (0.141)
Gender
Male 25 (48.1) 6 2 1 34
Female 27 (51.9) 4 1 1 33
Total 52 15 67
χ2 (P value) 0.796 (0.851)









Age in months 45.0±9.2 42.1±11.0 0.165 0.299
Duration of HIV 
diagnosis in months
14.9±10.9 10.5±7.7 0.034 0.151
Duration of use of 
HAART in months
11.7±10.2 4.4±7.2 0.012 0.011
Hb in g/dl 10.5±1.1 10.3±1.6 0.066 0.716
CD4% 22.3±9.8 21.0±9.6 0.748 0.663
HIV=Human immunodeficiency virus, HAART=Highly active antiretroviral 
therapy
Table 7: Correlation between weight‑for‑height value 
and age of subjects, duration of HIV infection, 





Age of subjects in months 0.293 0.016
Duration of HIV diagnosis in months 0.460 <0.001
Duration of HAART treatment in months 0.477 <0.001
Haemoglobin level of subjects in g/dl −0.088 0.477
Neutrophil count of subjects in cells/mm3 −0.069 0.579
Platelet count of subjects in 109/l 0.209 0.090
CD4% 0.095 0.445
HIV=Human immunodeficiency virus, HAART=Highly active antiretroviral 
therapy
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cytokines which are produced by HIV‑infected lymphocytes, 
monocytes, and macrophages.[6] In advanced HIV disease, 
there is corresponding increase in viral load and decrease in 
number and function of CD4 cells.[18] The increase in viral 
load results in elaborated production of cytokines by the 
increased number of HIV‑infected lymphocytes, monocytes, 
and macrophages. This may explain why HIV‑infected 
children with anemia were in advanced stage of the disease 
and severely immunosuppressed.
The study subjects with anemia were receiving zidovudine 
in their HAART combination therapy. Although treatment 
with HAART improves anemia in most HIV positive 
children,[8] Zidovudine based HAART has been shown to be 
a risk factor for the development of anemia in HIV positive 
children as it causes myelosuppression.[5,7,14] Okechukwu 
and coworkers[7] found that children on zidovudine based 
HAART were at higher risk for anemia than those on 
stavudine based HAART. Zidovudine intake is also an 
independent predictor of persistent anemia in those who 
had anemia prior to commencement of zidovudine based 
HAART.[5] Some studies[3,4,9] documented high prevalence 
of anemia in HAART naïve HIV positive children, thus 
highlighting the depressant effect of HIV on hemopoiesis.[19] 
Furthermore, we found that those with anemia had shorter 
duration of HAART treatment compared to those without 
anemia.
This study demonstrated that malnutrition occurs in HIV 
positive children as did the study by Bachou et al.,[9] who 
documented 43.0% prevalence of edematous malnutrition 
in HAART naïve children. The use of HAART has 
been shown to improve the nutritional indices of HIV 
positive children.[20] In this study, 47% of those who were 
malnourished were not on HAART treatment and the 
remaining half on treatment had a significant shorter 
duration of treatment. The effect of HAART on nutritional 
status could be attributed to a reduction in viral load and 
subsequent decrease in body metabolic rate that usually 
accompanies infectious processes. It is also pertinent to 
note that there was no demonstrable association between 
nutritional status and Hb level in this study, which is similar 
to the finding by Ira and Bhushan.[4] This could be because 
the anthropometric indices used in calculating nutritional 
status in that[4] and the index study assess macronutrient 
deficiency, whereas deficiencies of micronutrients such as 
iron, vitamin B complex, and folic acid deficiencies are 
factors associated with anemia.[17]
We did not find severe neutropenia or thrombocytopenia 
in our study, although malnourished subjects and those on 
HAART had comparatively low neutrophil and platelet 
counts. Myelosuppression consequent on HAART treatment 
and malnutrition could have contributed to this finding. 
However, in a study on populations who were HAART 
naïve, Ira and Bhushan[4] found the prevalence rates of 2 and 
10%, respectively for neutropenia and thrombocytopenia. 
In addition to their subjects being HAART naïve, 
they[4] defined neutropenia as absolute neutrophil count less 
than 1,500 mm3 and thrombocytopenia as platelet count 
less than 150,000 mm3, which could explain the observed 
prevalence rates.
As been documented, myelosuppression in HIV‑infected 
children can result from zidovudine based HAART 
regimen[5,7,14] or from overwhelming cytokines in absence of 
HAART treatment.[6] Therefore, the presence or absence of 
hematological abnormalities in these children will depend 
on the balance between the myelosuppression and other 
risk factors such a micronutrient deficiency.
Conclusion
Hematological abnormalities and malnutrition occur in 
HIV positive children. Anemia is a common hematological 
abnormality and has a direct relationship between 
CD4 cell counts. The older child and those with longer 
duration of HIV diagnosis and HAART treatment were 
more malnourished. Further study, on a larger population 
of children, to ascertain the role of other factors, such as 
malaria and micronutrient deficiency, which may contribute 
to anemia and malnutrition in HIV positive children, is 
recommended.
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